Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

ERK1/2 antibody

This Mouse Monoclonal antibody specifically detects ERK1/2 in WB, ELISA, IHC and FACS. It exhibits reactivity toward Human and Mouseand has been mentioned in 1 publication.
Catalog No. ABIN1724731

Quick Overview for ERK1/2 antibody (ABIN1724731)

Target

See all ERK1/2 (MAPK1/3) Antibodies
ERK1/2 (MAPK1/3) (Mitogen-Activated Protein Kinase 1/3 (MAPK1/3))

Reactivity

  • 179
  • 156
  • 151
  • 21
  • 21
  • 18
  • 7
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Human, Mouse

Host

  • 140
  • 42
  • 4
Mouse

Clonality

  • 134
  • 52
Monoclonal

Conjugate

  • 84
  • 9
  • 6
  • 5
  • 5
  • 5
  • 5
  • 5
  • 5
  • 5
  • 5
  • 5
  • 5
  • 5
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 2
  • 1
  • 1
This ERK1/2 antibody is un-conjugated

Application

  • 139
  • 66
  • 51
  • 50
  • 44
  • 35
  • 24
  • 24
  • 21
  • 13
  • 5
  • 4
  • 3
Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Flow Cytometry (FACS)

Clone

3F8
  • Purpose

    p44/42 MAPK (Erk1/2) Antibody

    Purification

    Ascitic fluid

    Immunogen

    Purified recombinant fragment of human MAPK expressed in E. Coli.

    Isotype

    IgG2b
  • Application Notes

    ELISA: 1/10000

    FCM: 1/200 - 1/400

    Restrictions

    For Research Use only
  • Format

    Liquid

    Buffer

    Ascitic fluid containing 0.03 % sodium azide.

    Preservative

    Sodium azide

    Precaution of Use

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Storage

    4 °C,-20 °C

    Storage Comment

    Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
  • Lønne, Masoumi, Lennartsson, Larsson: "Protein kinase Cdelta supports survival of MDA-MB-231 breast cancer cells by suppressing the ERK1/2 pathway." in: The Journal of biological chemistry, Vol. 284, Issue 48, pp. 33456-65, (2009) (PubMed).

  • Target

    ERK1/2 (MAPK1/3) (Mitogen-Activated Protein Kinase 1/3 (MAPK1/3))

    Alternative Name

    p44/42 MAPK (Erk1/2)

    Background

    Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines and is an important target in the diagnosis and treatment of cancer. Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family as well as Mos and Tpl2/Cot. MEK1 and MEK2 are the primary MAPKKs in this pathway. MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK and the transcription factor Elk-1. p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs, along with MEK inhibitors such as U0126 and PD98059.

    Molecular Weight

    42 kDa

    Gene ID

    5594

    UniProt

    P28482
You are here:
Chat with us!